ObjectiveTo investigate the mechanism of Yangxin Tongmai Formula （养心通脉方， YTF） in trea-ting coronary heart disease with blood stasis syndrome based on DNA methylation. MethodsSeventy-two SD rats were randomly divided into a control group （n=12） and a modeling group （n=60）. The modeling group was subjected to a high-fat diet， intragastric administration of vitamin D3， and subcutaneous injection of isoprenaline to establish the rat model of coronary heart disease with blood stasis syndrome. Forty-one successfully modeled rats were then randomly allocated into model group， YTF low-， medium-， and high-dose groups， and the atorvastatin calcium group， with 8 rats in each group and 1 rat reserved. The YTF low-， medium-， and high-dose groups received YTF at 6， 12， and 18 g/（kg·d） by gavage， respectively. The atorvastatin calcium group received atorvastatin calcium tablets at 1.8 mg/（kg·d） by gavage. The control group and the model group received 0.9% sodium chloride injection at 4 ml/（kg·d） by gavage. All administrations were performed once daily for 3 weeks. Twenty-four hours after the last administration， serum lipid levels including total cholesterol （TC）， triglycerides （TG）， low-density lipoprotein cholesterol （LDL-C）， and high-density lipoprotein cholesterol （HDL-C）， myocardial enzymes including cardiac troponin T （cTnT）， creatine kinase MB （CK-MB）， and lactate dehydrogenase （LDH）， and inflammatory factors including interleukin-1β （IL-1β） and interleukin-10 （IL-10） were detected by ELISA. Pathological changes in myocardial tissue were observed via HE staining. Whole blood DNA methylation sequencing was used to analyze differential methylation gene expression among the control group， model group， and YTF high-dose group. Western Blotting was used to verify the protein levels of the key genes and downstream signaling pathways. ResultsCompared to the control group， the model group showed increased levels of TC， TG， LDL-C， cTnT， CK-MB， LDH， and IL-1β， along with decreased levels of HDL-C and IL-10 （P＜0.05 or P＜0.01）. Compared to the model group， all treatment groups exhibited decreased levels of TC， LDL-C， CK-MB， and LDH， along with increased IL-10 levels. Among these， the high-dose YTF group demonstrated superior efficacy in reducing cTnT levels compared to the other TCM groups （P＜0.05 or P＜0.01）. HE staining indicated that the YTF high-dose group ameliorated myocardial cell swelling， disordered arrangement， pyknosis， and disappearance of nuclei， thereby reducing myocardial cell damage. Whole blood DNA methylation sequencing identified 240 differentially methylated genes shared by the control group， model group， and YTF high-dose group， including 109 hypermethylated and 131 hypomethylated genes； eif2ak3 was identified as a key differentially methylated gene. Compared to the control group， the model group exhibited increased protein levels of eukaryotic translation initiation factor 2 alpha kinase 3 （eIf2ak3）， phosphorylated protein kinase RNA-like endoplasmic reticulum kinase （p-PERK）， activating transcription factor 4 （ATF4）， C/EBP homologous protein （CHOP）， and Bax， along with a decreased level of B-cell lymphoma-2 （Bcl-2） protein （P＜0.05 or P＜0.01）. Compared to the model group， the YTF high-dose group showed decreased protein levels of eIf2ak3， p-PERK， ATF4， CHOP， and Bax， and an increased level of Bcl-2 protein （P＜0.05 or P＜0.01）. ConclusionYTF may regulate key differentially methylated genes such as eIf2ak3 and the PERK/ATF4/CHOP signaling pathway， thereby inhibiting endoplasmic reticulum stress， reducing myocardial cell apoptosis， and exerting therapeutic effects in coronary heart disease blood stasis syndrome.

ObjectiveTo observe the effect of Yangxin Tongmai Formula （养心通脉方） by midnight-noon ebb-flow administration method for rat models of premature coronary heart disease （PCHD） with blood stasis syndrome， and to explore the possible mechanism of action from the perspective of DNA methylation differential gene expression. MethodsThere were 3 SD rats in each of the blank group， model group and Yangxin Tongmai Formula group， and the rats in the model group and Yangxin Tongmai Formula group were fed with high-fat chow plus vitamin D3 by gavage plus isoproterenol hydrochloride by subcutaneous injection to construct rat models of PCHD with blood stasis syndrome. After successful modelling， rats in Yangxin Tongmai Formula group were gavaged with 18 g/（kg‧d） of Yangxin Tongmai Formula， and rats in blank group and the model group were gavaged with 4 ml/（kg‧d） of 0.9% NaCl solution， and serum samples of rats in each group were collected for DNA methylation sequencing after 3 weeks to screen for the relevant DNA methylation differentiation genes. In addition， rats with successful modelling of PCHD with blood stasis were randomly divided into model group， Yangxin Tongmai Formula with midnight-noon ebb-flow administration method group ［18 g/（kg‧d） of Yangxin Tongmai Formula was gavaged twice in the heart channel period （12：00） and pericardium channel period （20：00）］， the Yangxin Tongmai Formula control group ［18 g/（kg‧d） of Yangxin Tongmai Formula was gavaged twice at 8：00 and 18：00］ and the Atorvastatin Calcium group ［atorvastatin calcium tablets solution 1.8 mg/（kg‧d） at the same intervention time as that in Yangxin Tongmai Formula control group］， and set up a blank group of 8 rats in each group. The model group and blank group were gavaged with 0.9% NaCl solution 4 ml/（kg‧d） for the same time as the Yangxin Tongmai Formula control group. After 3 weeks of gavage， the blood lipids ［including total cholesterol （TC）， low-density lipoprotein （LDL）， high-density lipoprotein （HDL）］ levels of rats in each group were detected； the HE staining of myocardial tissues and thoracic aorta was used to observe the pathomorphological changes； the levels of serum inflammation indexes ［tumour necrosis factor alpha （TNF-alpha）， lipopolysaccharide （LPS）， and interleukin 10 （IL-10）］ were detected； immunoprecipitation-realtime fluorescence quantitative PCR was used to detect the relative expression of cardiac tissue screening differential genes. ResultsThe genes screened for differentially methylated regions were calmodulin 2 （Calm2）， calcium voltage-gated channel subunit α1s （Cacna1s）， and phospholipase Cβ1 （Plcb1）. Compared with the blank group， rats in the model group showed elevated levels of TC， LDL， TNF-α and LPS， and decreased levels of HDL and IL-10 （P＜0.05 or P＜0.01）； HE staining showed obvious swelling of myocardial fibres， accompanied by a large number of inflammatory cell infiltration， and thickening of the inner wall of the aortic vessels with internal wall damage， which was visible as a large number of lipid cholesterol crystals and obvious inflammatory cell infiltration. Compared with the model group， the TC， LDL， TNF-α and LPS contents of rats in the Yangxin Tongmai Formula with midnight-noon ebb-flow administration method group， the Yangxin Tongmai Formula control group， and the atorvastatin calcium group all reduced， and the contents of HDL and IL-10 all elevated （P＜0.05）， with the improvement of myocardial tissue damage and the reduction of inflammatory infiltration， and the improvement of the damage of the inner lining of the thoracic aorta and the reduction of lipid infiltration. Compared with Yangxin Tongmai Formula control group， LDL， TNF-α and LPS contents reduced， and IL-10 contents increased in the midnight-noon ebb-flow administration method group （P＜0.05）. Compared with the model group， the relative expression of Calm2 and Plcb1 genes decreased and the relative expression of Cacna1s gene increased in Yangxin Tongmai Formula control group and the midnight-noon ebb-flow administration method group （P＜0.05）； compared with the Yangxin Tongmai Formula control group， the relative expression of Calm2 gene decreased and the relative expression of Cacna1s gene increased in the midnight-noon ebb-flow administration method group （P＜0.05）. ConclusionThe intervention of Yangxin Tongmai Formula in the heart channel period （12：00） and pericardium channel period （20：00） was more effective in improving the blood lipid level， inhibiting inflammation， and improving myocardial tissue damage in rats of PCHD with blood stasis syndrome， and Calm2 and Cacna1s genes may be the key targets of Yangxin Tongmai Formula in intervening the blood stasis syndrome of PCHD.

OBJECTIVE To analyze the status and characteristics of hospital-associated infection in a three-A hospi-tal from 2023 to 2024,and to identify directions for intervention in hospital-associated infection.METHODS The hospital-associated infection data of a three-A hospital from 2023 to 2024 were analyzed,including the overall trend of hospital-associated infection,the top three departments with the highest hospital-associated infection rates,the distribution of pathogens,infection sites and patient ages.RESULTS From 2023 to 2024,a total of 145 915 patients were monitored,with 1 673 cases of hospital-associated infection,resulting in a hospital-associat-ed infection rate of 1.15％.The hospital-associated infection rate in 2024 was 1.06％(831/78 284),which was lower than that in 2023(P=0.001).The top three departments with the highest hospital-associated infection rates were the intensive care unit,the emergency intensive care unit(EICU)and the cadre ward.Among the de-tected pathogens,gram-negative bacteria were predominantly Acinetobacter baumannii(26.21％),gram-positive bacteria were predominantly Staphylococcus aureus(4.86％)and fungi were predominantly Candida glabrata(13.89％).There were statistically significant differences in the proportions of Proteus vulgaris,Serratia lique-faciens,Burkholderia cepacia and gram-positive bacteria between the two years(P＜0.05).The main hospital-associated infection sites were the respiratory tract,urinary tract and surgical site.The hospital-associated infec-tion rate was high among elderly patients,particularly in the cadre ward.CONCLUSIONS The departments with high incidence of hospital-associated infection are the intensive care unit,EICU and cadre ward.The main patho-gen is A.baumannii,with the respiratory tract being the primary site of infection.It is necessary to strengthen prevention and control measures for high-risk departments,key pathogens and common infection sites to effective-ly reduce the incidence of hospital-associated infection.

Objective To explore the potential contributors and obstacles of evidence translation for airway hu-midification management in hospitalized patients with laryngectomy tracheostomy and non-mechanical ventilation,so as to provide references for clinical evidence-based practice.Methods An interview outline and questionnaire were developed according to the consolidated framework for implementation research(CFIR).Using purposive sampling,12 healthcare professionals from Department of Otorhinolaryngology,Head and Neck Surgery of a tertiary hospital in Shanxi Province were recruited for semi-structured interviews,and thematic analysis was applied to extract main themes.The interview themes were transformed into survey items,and a survey was conducted among 42 healthcare professionals in the same department.Results Totally 16 contributors and 20 obstacles were identified across 4 domains:the credibility of the evidence and research team,the external support environment for evidence-based practice,the internal conditions for evidence-based practice,and the role recognition of implementers.Contributors include efficient internal collaboration and communication,and rigorous processes for evidence acquisition.Obstacles include insufficient educational resources,low patient knowledge acceptance capacity,lack of professional value a-mong healthcare staff.Conclusion Evidence translation of the humidification management for patients with non-mechanical ventilation after laryngectomy and tracheostomy was influenced by various factors.Future efforts should focus on constructing targeted airway humidification education content and an evaluation index system,and enhanc-ing the professional value and practical leadership of nursing staff.

Objective:To comprehensively identify, describe and evaluate the research evidence on the application of ERAS in perioperative head and neck cancer by using the method of evidence mapping, so as to understand the research status and provide reference for clinical practice and future research in this field.Methods:Adopting an evidence-integrated research approach, PubMed, Embase, CINAHL, Web of Science, Cochrane Library, CNKI, Wanfang, VIP and Chinese Biomedical Literature Database were searched by computer. In addition, relevant references and grey literature databases such as OpenGrey were manually searched until August 25, 2024, to screen and summarize the included literature, and different quality evaluation tools were used to evaluate the quality of the included studies. The present research situation was presented with text and graphs.Results:A total of 105 articles were included, including 101 original studies and 4 systematic reviews/Meta-analyses. The number of published literature showed an increasing trend over time, but it fluctuated in a zigzag pattern. The most published studies were in China, and the study population was mainly patients with laryngeal and oral cancer, with a sample size of 51-100 cases. The results of methodology quality evaluation showed that the quality of most studies was relatively low. The intervention measures mainly involved 9 subjects, such as pre-rehabilitation, nutritional support, prevention of nausea and vomiting, and the outcome indicators involved 2 aspects related to patients and hospital. More attention was paid to outcome indicators such as complication rate and length of stay, while less attention was paid to outcome indicators such as condition of sputum and survival time. Most outcome effects were shown to be "beneficial", but some outcome effects were still controversial.Conclusions:ERAS has generally shown positive effects in perioperative application of head and neck cancer, but the quality of most studies is low. More high-quality clinical studies are needed in the future to provide more sufficient evidence for the application of ERAS in this field.

OBJECTIVE To analyze the status and characteristics of hospital-associated infection in a three-A hospi-tal from 2023 to 2024,and to identify directions for intervention in hospital-associated infection.METHODS The hospital-associated infection data of a three-A hospital from 2023 to 2024 were analyzed,including the overall trend of hospital-associated infection,the top three departments with the highest hospital-associated infection rates,the distribution of pathogens,infection sites and patient ages.RESULTS From 2023 to 2024,a total of 145 915 patients were monitored,with 1 673 cases of hospital-associated infection,resulting in a hospital-associat-ed infection rate of 1.15％.The hospital-associated infection rate in 2024 was 1.06％(831/78 284),which was lower than that in 2023(P=0.001).The top three departments with the highest hospital-associated infection rates were the intensive care unit,the emergency intensive care unit(EICU)and the cadre ward.Among the de-tected pathogens,gram-negative bacteria were predominantly Acinetobacter baumannii(26.21％),gram-positive bacteria were predominantly Staphylococcus aureus(4.86％)and fungi were predominantly Candida glabrata(13.89％).There were statistically significant differences in the proportions of Proteus vulgaris,Serratia lique-faciens,Burkholderia cepacia and gram-positive bacteria between the two years(P＜0.05).The main hospital-associated infection sites were the respiratory tract,urinary tract and surgical site.The hospital-associated infec-tion rate was high among elderly patients,particularly in the cadre ward.CONCLUSIONS The departments with high incidence of hospital-associated infection are the intensive care unit,EICU and cadre ward.The main patho-gen is A.baumannii,with the respiratory tract being the primary site of infection.It is necessary to strengthen prevention and control measures for high-risk departments,key pathogens and common infection sites to effective-ly reduce the incidence of hospital-associated infection.

Objective:To comprehensively identify, describe and evaluate the research evidence on the application of ERAS in perioperative head and neck cancer by using the method of evidence mapping, so as to understand the research status and provide reference for clinical practice and future research in this field.Methods:Adopting an evidence-integrated research approach, PubMed, Embase, CINAHL, Web of Science, Cochrane Library, CNKI, Wanfang, VIP and Chinese Biomedical Literature Database were searched by computer. In addition, relevant references and grey literature databases such as OpenGrey were manually searched until August 25, 2024, to screen and summarize the included literature, and different quality evaluation tools were used to evaluate the quality of the included studies. The present research situation was presented with text and graphs.Results:A total of 105 articles were included, including 101 original studies and 4 systematic reviews/Meta-analyses. The number of published literature showed an increasing trend over time, but it fluctuated in a zigzag pattern. The most published studies were in China, and the study population was mainly patients with laryngeal and oral cancer, with a sample size of 51-100 cases. The results of methodology quality evaluation showed that the quality of most studies was relatively low. The intervention measures mainly involved 9 subjects, such as pre-rehabilitation, nutritional support, prevention of nausea and vomiting, and the outcome indicators involved 2 aspects related to patients and hospital. More attention was paid to outcome indicators such as complication rate and length of stay, while less attention was paid to outcome indicators such as condition of sputum and survival time. Most outcome effects were shown to be "beneficial", but some outcome effects were still controversial.Conclusions:ERAS has generally shown positive effects in perioperative application of head and neck cancer, but the quality of most studies is low. More high-quality clinical studies are needed in the future to provide more sufficient evidence for the application of ERAS in this field.

Objective To explore the potential contributors and obstacles of evidence translation for airway hu-midification management in hospitalized patients with laryngectomy tracheostomy and non-mechanical ventilation,so as to provide references for clinical evidence-based practice.Methods An interview outline and questionnaire were developed according to the consolidated framework for implementation research(CFIR).Using purposive sampling,12 healthcare professionals from Department of Otorhinolaryngology,Head and Neck Surgery of a tertiary hospital in Shanxi Province were recruited for semi-structured interviews,and thematic analysis was applied to extract main themes.The interview themes were transformed into survey items,and a survey was conducted among 42 healthcare professionals in the same department.Results Totally 16 contributors and 20 obstacles were identified across 4 domains:the credibility of the evidence and research team,the external support environment for evidence-based practice,the internal conditions for evidence-based practice,and the role recognition of implementers.Contributors include efficient internal collaboration and communication,and rigorous processes for evidence acquisition.Obstacles include insufficient educational resources,low patient knowledge acceptance capacity,lack of professional value a-mong healthcare staff.Conclusion Evidence translation of the humidification management for patients with non-mechanical ventilation after laryngectomy and tracheostomy was influenced by various factors.Future efforts should focus on constructing targeted airway humidification education content and an evaluation index system,and enhanc-ing the professional value and practical leadership of nursing staff.

Objective:To analyze the temporal trends of the incidence rate of tuberculosis (TB) in Shaanxi Province and provide a reference for WHO to control the prevalence of TB effectively.Methods:Joinpoint regression was used to analyze the trend of the incidence rate of TB in Shaanxi Province from 2004 to 2022, and the seasonal autoregressive moving average model was used to forecast the incidence rate of TB in Shaanxi Province to 2030.Results:The incidence rate of TB in Shaanxi Province decreased from 90.896/100 000 in 2004 to 35.364/100 000 in 2022, showing a general downward trend (AAPC=-7.72%, P<0.001). From 2014 to 2019, the reduction trend slowed down (APC=-0.69%, P=0.814), of which the largest decline occurred from 2019 to 2022 (APC=-13.26%, P=0.010). The predicted incidence rate of TB in Shaanxi Province from 2020 to 2022 was higher than the reported incidence rate, with the expected incidence rate of 51.342/100 000 in 2022 and 43.468/100 000 in 2030. Conclusion:The incidence rate of TB in Shaanxi Province shows a downward trend from 2004 to 2022, but the decline has shrunk in recent years. It is predicted that the downward trend will continue to slow down by 2030.

Objective:To analyze the temporal trends of the incidence rate of tuberculosis (TB) in Shaanxi Province and provide a reference for WHO to control the prevalence of TB effectively.Methods:Joinpoint regression was used to analyze the trend of the incidence rate of TB in Shaanxi Province from 2004 to 2022, and the seasonal autoregressive moving average model was used to forecast the incidence rate of TB in Shaanxi Province to 2030.Results:The incidence rate of TB in Shaanxi Province decreased from 90.896/100 000 in 2004 to 35.364/100 000 in 2022, showing a general downward trend (AAPC=-7.72%, P<0.001). From 2014 to 2019, the reduction trend slowed down (APC=-0.69%, P=0.814), of which the largest decline occurred from 2019 to 2022 (APC=-13.26%, P=0.010). The predicted incidence rate of TB in Shaanxi Province from 2020 to 2022 was higher than the reported incidence rate, with the expected incidence rate of 51.342/100 000 in 2022 and 43.468/100 000 in 2030. Conclusion:The incidence rate of TB in Shaanxi Province shows a downward trend from 2004 to 2022, but the decline has shrunk in recent years. It is predicted that the downward trend will continue to slow down by 2030.